Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 4, Avril 2007
Page(s) 391 - 398
Section M/S revues
DOI https://doi.org/10.1051/medsci/2007234391
Publié en ligne 15 avril 2007
  1. Teng TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15 : 369–90.
  2. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev 1996; 18 : 99–117.
  3. Nokes DJ, Anderson RM. Vaccine safety versus vaccine efficacy in mass immunisation programs. Lancet 1991; 338 : 1309–12.
  4. Jefferson T, Demicheli V, Pratt M. Evidence-based vaccinology: the work of the Cochrane vaccine field. J Epidemiol Community Health 1998; 52 : 207–8.
  5. Dittmann S. Vaccine safety: risk communication: a global perspective. Vaccine 2001; 19 : 2446–56.
  6. André F. Vaccination contre la varicelle. In : Vaccinations, actualités et perspectives. Expertise collective de l’Inserm. Paris : Éditions Inserm, 1999.
  7. Anderson RM, Donnelly CA, Gupta S. Vaccine design, evaluation, and community-based use for antigenically variable infectious agents. Lancet 1997; 350 : 1466–70.
  8. ACIP, CDC. Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1996; 45 (RR-11) : 1–36.
  9. Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291 : 851–5.
  10. Boelle PY. Épidémiologie théorique et vaccination. Rev Med Interne 2007 (sous presse).
  11. Halloran ME. Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am 1996; 10 : 631–55.
  12. Bonmarin I, Levy-Bruhl D. La rougeole en France : impact épidémiologique d’une couverture vaccinale sub-optimale. Eurosurveillance 2002; 7 : 55–60.
  13. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287 : 606–11.
  14. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005; 294 : 797–802.
  15. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352 : 450–8.
  16. Anderson RM, Donnelly CA, Gupta S. Vaccine design, evaluation, and community-based use for antigenically variable infectious agents. Lancet 1997; 350 : 1466–70.
  17. Levine MM, Levine OS. Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. Lancet 1997; 350 : 1386–92.
  18. Zimmerman RK, Schlesselman JJ, Mieczkowski TA, et al. Physician concern about vaccine adverse effects and potential litigation. Arch Pediatr Adolesc Med 1998; 152 : 12–9.
  19. Comité Technique des Vaccinations, Direction Générale de la santé. Guide des vaccinations. Paris : Comité français d’éducation pour la santé (CFES), 2006.
  20. Bonmarin I, Ndiaye B, Seringe E, Levy-Brühl D. Épidémiologie de la varicelle en France. BEH 2005; 2005 : 30–2.
  21. Boëlle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 2002; 129 : 599–606.
  22. Hanslik T, Boëlle PY, Schwarzinger M, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003; 21 : 3614–22.
  23. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental ? Lancet 1998; 351 : 611–2.
  24. Loupi E, Baudard S, Debois H, Pignato F. Les risques associés aux vaccinations. Ann Med Interne 1998; 149 : 361–71.
  25. Gershon AA, M. Takahashi, Seward J. Vaccines, 4th ed. In : Plotkin SA, Orenstein WA, eds. Philadelphia : Saunders, 2004 : 783–824.
  26. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005; 18 : 70–80.
  27. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J Pediatr 1990; 116 : 184–9.
  28. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191 : 2002–7.
  29. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Reports 1997; 112 : 10–20.
  30. Singleton JA, Lloyd JC, Mootrey GT, et al. VAERS Working Group. An overview of the vaccine adverse event rporting system (VAERS) as a surveillance system. Vaccine 1999; 17 : 2908–17.
  31. Braun MM, Ellenberg SS. Descriptive epidemiology of advserse events after immunization: reports of the vaccine adverse event reporting system, 1991-1994. J Pediatr 1997; 131 : 529–35.
  32. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19 : 916–23.
  33. Gershon AA. Varicella vaccine: rare serious problems-but the benefits still outweigh the risks. J Infect Dis 2003; 188 : 945–7.
  34. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284 : 1271–9.
  35. Levin MJ, Dahl KM, Weinberg A, et al. Development of resistance to aciclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003; 188 : 954–9.
  36. Hanslik T, Blanchon T, Alvarez Fabián P. Vaccination des adultes contre la varicelle et le zona. Rev Med Interne 2007 (sous presse).
  37. Valleron AJ. Mise en évidence des faits et recherche des causes en épidémiologie environnementale : enjeux méthodologiques. CR Acad Sci Paris SerIII 2000; 323 : 617–28.
  38. Hill AB. The environment and disease: association or causation ? Proc R Soc Med 1965; 58 : 295–300.
  39. Kramer MS. Difficulties in assessing the advserse effects of drugs. Br J Clin Pharmacol 1981; 11 (suppl 1) : S105–10.
  40. Institute of Medicine. Causality and evidence. In : Stratton KR, Howe CJ, Johnston RB, eds. Adverse events associated with childhood vaccine, evidence bearing on causality. Washington DC : National Academy Press, 1994 : 19–33.
  41. World Health Organization. Causality assessement of adverse events following immunization. Wkly Epidemiol Rec 2001; 76 : 85–92.
  42. Collet JP, MacDonald N, Cashman N, Pless R, Advisory committee in causality assessment. Monitoring signals for vaccine safety: the assessment of individual adverse event report by an expert advisory committee. Bull World Health Org 2000; 78 : 178–85.
  43. Chauvin P, Valleron AJ. Persistence of susceptibility to measles in France despite routine immunization: a cohort analysis. Am J Publ Health 1999, 89 : 79–81.
  44. Levy-Bruhl D, Desenclos JC, Rebiere I, Drucker J. Central demyelinating disorders and hepatitis B vaccination: a risk-benefit approach for pre-adolescent vaccination in France. Vaccine 2002; 20 : 2065–71.
  45. Conseil Supérieur d’Hygiène Publique de France. Calendrier vaccinal 2006. BEH 2006; n° 2 : 211–6.
  46. Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987; 68 : 562–9.
  47. Mitchell DM, Fitzharris P, Knight RA, et al. Kinetics of specific anti-influenza antibody production by cultured lymphocytes from patients with systemic lupus erythematosus following influenza immunization. Clin Exp Immunol 1982; 49 : 290–6.
  48. Turner-Stokes L, Cambridge G, Corcoran T, et al. In vitro response to inluenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988; 47 : 532–5.
  49. McDonald E, Jarret MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984; 11 : 306–8.
  50. Ioannou Y, Isenberg DA. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus 1999; 8 : 497–501.
  51. Hanslik T, Wechsler B, Vaillant JN, et al. A survey of physicians’ vaccine risk perception and immunization practices for subjects with immunological diseases. Vaccine 2000; 19 : 908–15.
  52. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999; 17 : S41–6.
  53. Slovic P. Perception of risk. Science 1987; 236 : 280–5.
  54. Analyse économique. In : Vaccinations, actualités et perspectives. Expertise collective de l’Inserm. Paris : Éditions Inserm, 1999 : 103–23.
  55. Teng TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15 : 369–90.
  56. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombotic therapy with tissue plasminogen activator as compared with streptokinase in acute myocardial infarction. N Engl J Med 1995; 332 : 1418–24.
  57. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271 : 375–81.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.